Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEAK-1 trial of casdatifan + cabozantinib versus placebo + cabozantinib in advanced clear cell renal cell carcinoma
jRCT2051260009Phase 3Recruiting
- Sponsor
- Arcus Biosciences
- Start
- May 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of casdatifan and cabozantinib in clear cell renal cell carcinoma (ccRCC) (2 arms), sponsored by Arcus Biosciences. Primary endpoint: Progression-free survival. Started May 2026; status: recruiting.
02
Drugs
casdatifancabozantinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on jRCT2051260009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051260009.